Record quarterly revenue driven by strong growth in SSi Mantra installations and proceduresFORT LAUDERDALE, Fla., May 13, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2026. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026. First Quarter 2026 Overview Revenue increased 116.8% to $11.1 million from $5.1 million in the first quarter of 2025.Gross margin expanded to 48.0% from 21.2% in the first quarter of 2025.Gross profit rose 390.0% to $5.3 million from $1.1 million in the first quarter of 2025.Net loss of $3.6 million, or $(0.02) per diluted share, compared to a net loss of $5.7 million, or $(0.03) per diluted share, in the first quarter of 2025.SSi Mantra surgical robotic system installations totaled 26, up 73.3% from 15 installations in the first quarter of 2025. As of March 31, 2026 Long-term debt of $0.Cash and cash equivalents totaled $16.0 million, excluding restricted cash.SSi Mantra cumulative installed base totaled 194 across eleven countries and cumulative surgeries reached 9,744, including 157 telesurgeries, 482 cardiac procedures and 161 pediatric surgeries. CEO Commentary Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the first quarter of 2026 we reported record quarterly revenue of $11.1 million, up 117% year over year, driven by robust growth in SSi Mantra installations and procedures. Strong adoption by hospitals and physicians reflects the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency. Among other developments in the quarter, we received regulatory approval for the SSi Mantra for multiple indications in Sri Lanka and Kenya and for telesurgery in Indonesia and the Philippines. We also successfully completed a private placement in March 2026 that provided SS Innovations with approximately $18.6 million in gross proceeds to fuel growth initiatives.” Dr. Srivastava continued, “Looking ahead, we aim to fortify our position as a leader in the substantial Indian market, expand our global footprint in underserved countries, and secure entry into the United States and European Union markets. We expect the U.S. Food and Drug Administration to complete its review of our 510(k) premarket notification for the SSi Mantra this year. Separately, we continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can also obtain in 2026. We are very excited about the growth runway ahead and remain steadfast in our commitment to democratizing access to advanced surgical robotic care.” Select Business Highlights in First Quarter 2025 In January 2026, the Company received regulatory approval for the SSi Mantra from the National Medicines Regulatory Authority (“NMRA”) in Sri Lanka and from the Pharmacy and Poisons Board (“PPB”) in Kenya.On March 9, 2026, the Company announced the completion of a private placement of its common stock, generating approximately $18.6 million in gross proceeds before deducting offering expenses, to support growth initiatives. In the offering, the Company offered and sold a total of 5,774,839 shares of common stock consisting of: an aggregate of 1,300,006 shares of common stock at an average price of $4.00 per share to certain of the Company’s directors and executive officers, or a total of approximately $5.2 million; and an aggregate of 4,474,833 shares of common stock at $3.00 per share, or approximately $13.4 million cumulatively, to non-affiliate investors.On March 18, 2026, the Company announced that the SSi Mantra surgical robotic system received approval for telesurgeries in Indonesia and the Philippines.    Revenue Breakdown and Summary of Installations / Surgeries CategoryQ1 2025Q1 2026VariancePercentageSystem sales$4,502,482$9,575,370$5,072,888 112.7%Instrument sales 477,208 1,151,228 674,020 141.2%Warranty sales 122,504 357,686 235,182 192.0%Lease income 18,416 17,082 (1,334)(7.2)%Total revenue$5,120,610$11,101,366$5,980,756 116.8%     SSi Mantra installations 15 26 11 73.3%Cumulative installed base1 78 194 116 148.7%     SSi Mantra surgeries 787 1,859 1,072 136.2%Cumulative surgeries1 3,568 9,744 6,176 173.1%  1 at period end About SS Innovations SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi Mantra The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana Tele Surgeon Console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures. Forward Looking StatementsThis press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investor Contact:The Equity Group        Kalle Ahl, CFA                T: (303) 953-9878        kahl@theequitygroup.com Devin Sullivan, Managing Director T: (212) 836-9608dsullivan@theequitygroup.com Media Contact:RooneyPartners LLCKate BarretteT: (212) 223-0561kbarrette@rooneypartners.com SS INNOVATIONS INTERNATIONAL, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)    As of    March 31,2026  December 31,2025 ASSETS       Current Assets:       Cash and cash equivalents  $15,979,714  $3,206,406 Restricted cash   7,631,336   5,937,650 Accounts receivable, net   14,054,376   12,398,542 Inventory   17,066,091   17,064,002 Prepaids and other current assets   11,530,000   10,166,823 Total Current Assets   66,261,517   48,773,423           Property, plant, and equipment, net   8,831,423   9,100,546 Right of use asset, net   2,499,490   2,754,020 Deferred tax assets, net   805,750   533,727 Accounts receivable, net-non current   7,265,911   8,566,654 Restricted cash- non current   394,630   458,964 Prepaids and other non current assets   4,488,168   4,038,883 Total Assets  $90,546,889  $74,226,217           LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY         Current Liabilities         Bank overdraft facility  $11,156,147  $11,442,948 Current portion of operating lease liabilities   576,237   579,169 Accounts payable   4,403,170   5,127,193 Deferred revenue   3,582,631   3,266,686 Accrued expenses & other current liabilities   6,326,818   5,825,702 Total Current Liabilities   26,045,003   26,241,698           Operating lease liabilities, less current portion   2,086,534   2,337,697 Deferred Revenue- non current   7,501,283   7,139,807 Other non current liabilities   390,656   288,764 Total Liabilities  $36,023,476  $36,007,966 Commitments and contingencies         Stockholders’ equity:                   Preferred stock, authorized 5,000,000 shares of Series A, Non-Convertible Preferred Stock, $0.0001 par value per share; 1,000 shares issued and outstanding as of March 31, 2026, and December 31, 2025   1   1 Common stock, 250,000,000 shares authorized, $0.0001 par value, 200,131,535 shares and 194,165,141 shares issued and outstanding as of March 31, 2026 and December 31, 2025 respectively   20,013   19,416 Accumulated other comprehensive income (loss)   (3,573,137)  (2,022,660)Additional paid in capital   116,549,124   95,111,511 Capital reserve   899,917   899,917 Accumulated deficit   (59,372,505)  (55,789,934)Total stockholders’ equity   54,523,413   38,218,251 Total liabilities and stockholders’ equity  $90,546,889  $74,226,217   SS INNOVATIONS INTERNATIONAL, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)    For The Three months ended    March 31,2026  March 31,2025         REVENUES         System sales   9,575,370   4,502,482 Instruments sale   1,151,228   477,208 Warranty sale   357,686   122,504 Lease income   17,082   18,416 Total revenue  $11,101,366  $5,120,610 Cost of revenue   (5,774,145)  (4,033,402)          GROSS PROFIT   5,327,221   1,087,208           OPERATING EXPENSES:         Research & development expense   995,440   1,010,095 Stock compensation expense   3,144,315   2,379,212 Depreciation and amortization expense   323,747   208,882 Selling, general and administrative expense   4,502,476   3,410,872 TOTAL OPERATING EXPENSES   8,965,978   7,009,061           Loss from operations   (3,638,757)  (5,921,853)          OTHER INCOME (EXPENSE):         Interest Expense   (284,051)  (379,905)Interest and other income, net   491,589   620,405 TOTAL INCOME, NET   207,538   240,500           LOSS BEFORE INCOME TAXES   (3,431,219)  (5,681,353)Income tax expense   151,352   – NET LOSS  $(3,582,571) $(5,681,353)          CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS                   NET LOSS  $(3,582,571) $(5,681,353)          OTHER COMPREHENSIVE INCOME (LOSS):         Foreign currency translation loss   (1,557,111)  6,876 Retirement Benefit   4,781   15,838 RECLASSIFICATION ADJUSTMENTS:         Retirement Benefit (1)   3,056   – Income tax effects relating to retirement benefit   (1,203)  – TOTAL OTHER COMPREHENSIVE LOSS   (1,550,477)  22,714 TOTAL COMPREHENSIVE LOSS  $(5,133,048) $(5,658,639) (1)These are reclassified to net loss and are included in other expenses in the condensed consolidated statements of operations. SS INNOVATIONS INTERNATIONAL, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)   For The Three months ended   March 31, 2026  March 31, 2025 Cash flows from operating activities:             Net loss $(3,582,571) $(5,681,353)Adjustments to reconcile net loss to net cash used in operating activities:        Depreciation and amortization  323,747   208,882 Operating lease expense  220,493   205,275 Interest Expense  43,555   155,015 Interest and other income, net  (415,465)  (140,928)Deferred income tax benefit  (301,036)  – Stock compensation expense  3,144,315   2,379,212 Provision for / (Reversal of) credit loss reserve, net  230,616   (422,711)Provision for slow moving inventory  (6,248)  –          Changes in operating assets and liabilities:        Accounts receivable, net  (245,111)  1,275,750 Inventory, net  4,159   (5,082,673)Deferred revenue  677,421   823,947 Prepaids and other assets  (2,066,322)  (1,003,604)Accounts payable  (704,764)  1,329,028 Income taxes payable, net  323,014   – Accrued expenses & other liabilities  256,441   48,331 Operating lease payment  (214,180)  (197,545)Net cash used in operating activities  (2,311,936)  (6,103,374)         Cash flows from investing activities:        Purchase of property, plant and equipment  (54,189)  (872,804)Net cash used in investing activities  (54,189)  (872,804)         Cash flows from financing activities:        Proceeds from bank overdraft facility (net)  (286,801)  (312,495)Proceeds from Private Investment in Public Equity, net of transaction costs  18,446,498   – Proceeds from issuance of convertible notes to principal shareholder  –   28,000,000 Repayment of convertible notes to principal shareholder, including interest  –   (4,212,637)Repayment of convertible notes to other investors, including interest  –   (1,068,849)Net cash provided by financing activities  18,159,697   22,406,019          Net change in cash  15,793,572   15,429,841 Effect of exchange rate on cash  (1,390,012)  25,412 Cash and cash equivalents at the beginning of the year  9,603,020   6,623,535 Cash and cash equivalents at end of the year $24,005,680  $22,078,788  

FORT LAUDERDALE, Fla., March 30, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company has received regulatory approval for the SSi Mantra surgical robotic system (the “SSi Mantra”), for multiple indications in Colombia, Oman, Sri Lanka and Kenya. The Company received regulatory approval for the SSi Mantra from the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (“INVIMA”) in Colombia in November 2025, from the Directorate General of Pharmaceutical Affairs and Drug Control (“DGPA&DC”) in Oman in November 2025, from the National Medicines Regulatory Authority (“NMRA”) in Sri Lanka in January 2026, and from the Pharmacy and Poisons Board (“PPB”) in Kenya in January 2026. SS Innovations believes that it is favorably positioned to address these underpenetrated markets given the SSi Mantra’s cost advantages combined with its advanced technology, differentiated features, ease of training, and user-friendliness. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We continue to expand SS Innovations’ global opportunity with an eye on democratizing access to cutting-edge robotic surgery for patients in underserved regions of the world. Over the past few months, our advanced, cost-efficient SSi Mantra surgical robotic system has received regulatory approval in Colombia, Oman, Sri Lanka, and Kenya. We are committed to decentralizing excellence in surgical robotic care in these new jurisdictions, among others, while pursuing the established United States and Europe Union markets. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra by mid-2026. Separately, we continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain in 2026.” To date, the SSi Mantra has been granted regulatory approval in eleven countries, including India and the following: Colombia Oman Ecuador Philippines Guatemala Sri Lanka Indonesia Ukraine Kenya United Arab Emirates    As of December 31, 2025, the SSi Mantra cumulative installed base totaled 168 across ten countries and cumulative surgeries reached 7,885, including 390 cardiac procedures and 121 pediatric surgeries. To date, more than 150 telesurgeries have been performed with the SSi Mantra. About SS Innovations SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi Mantra The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana Tele Surgeon Console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures. Forward Looking StatementsThis press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investor Contact:The Equity GroupKalle Ahl, CFAT: (303) 953-9878kahl@theequitygroup.com Devin Sullivan, Managing Director T: (212) 836-9608dsullivan@theequitygroup.com Media Contact:RooneyPartners LLCKate BarretteT: (212) 223-0561kbarrette@rooneypartners.com

Strong growth in SSi Mantra installations, procedures and revenuesFORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and twelve months ended December 31, 2025. The Company also filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission on March 10, 2026. Fourth Quarter 2025 Overview Revenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024.Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024.Gross profit rose 60.7% to $6.4 million from $4.0 million in the fourth quarter of 2024.Net loss of $2.5 million, or $(0.01) per diluted share, compared to a net loss of $1.9 million, or $(0.01) per diluted share, in the fourth quarter of 2024.SSi Mantra surgical robotic system installations totaled 40, up 81.8% from 22 installations in the fourth quarter of 2024 and up 48.1% from 27 installations in the third quarter of 2025. Full Year 2025 Overview Revenue increased 105.7% to $42.5 million from $20.6 million in 2024.Gross margin expanded to 46.0% from 40.9% in 2024.Gross profit rose 131.2% to $19.5 million from $8.5 million in 2024.Net loss of $12.1 million, or $(0.06) per diluted share, compared to net loss of $19.2 million, or $(0.11) per diluted share, in 2024.SSi Mantra surgical robotic system installations totaled 103, up 119.1% from 47 installations in 2024. As of December 31, 2025 Long-term debt of $0.Cash and cash equivalents totaled $3.2 million, excluding restricted cash.SSi Mantra cumulative installed base totaled 168 across ten countries and cumulative surgeries reached 7,885, including 120 telesurgeries, 390 cardiac procedures and 121 pediatric surgeries. CEO Commentary Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the fourth quarter of 2025, we achieved strong growth in SSi Mantra installations, procedures and revenues, capping off a successful year for SS Innovations. Among our accomplishments in 2025, we gained significant share of the surgical robotics market in India, expanded into new global geographies, and progressed along the regulatory pathways required for entering the United States and European Union markets. We also continued to pioneer robotic telesurgery, attaining multiple new procedure milestones and unveiling cutting-edge innovations such as the Tele Surgeon Console and MantraM mobile robotic telesurgery unit. Finally, the uplisting of our shares to Nasdaq has enhanced market awareness of our growth story and expanded our audience of potential investors.” Dr. Srivastava continued, “After quarter-end we completed a private placement of common stock, which brings us new long-term oriented institutional investors and approximately $18.6 million of gross proceeds aimed to fuel SS Innovations’ growth in 2026 and beyond. Significant insider participation in this financing reflects our strong confidence in SS Innovations’ future. We will continue to invest in enhancements to our advanced, cost-effective SSi Mantra surgical robotic system and expand our capacity to lead the vast Indian market, penetrate underserved global geographies, and prepare for our entry into the United States and European Union. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra by mid-2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can also obtain this year. In conclusion, we expect continuing strong growth in 2026 as we deploy the SSi Mantra in existing and new markets, increasing access to world-class surgical robotic care.” Select Business Highlights in Fourth Quarter 2025 On November 6, 2025, the Company announced the successful completion of the first telesurgery performed with the SSi Mantra Tele Surgeon Console.On December 5, 2025, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (the “FDA”) for the SSi Mantra surgical robotic system, covering multiple indications including general, urological, colorectal, gynecological and cardiac surgeries. Subsequent Events On January 6, 2026, the Company announced the development of five new 5-millimeter surgical instruments for clinical use across multiple specialties, including pediatric, cardiac, and head and neck surgery, among other procedures involving smaller anatomical structures.On March 9, 2026, the Company announced the completion of a private placement of its common stock, generating approximately $18.6 million in gross proceeds before deducting offering expenses, to support growth initiatives. In the offering, the Company offered and sold a total of 5,774,839 shares of common stock consisting of: an aggregate of 1,300,006 shares of common stock at an average price of $4.00 per share to certain of the Company’s directors and executive officers, or a total of approximately $5.2 million; and an aggregate of 4,474,833 shares of common stock at $3.00 per share, or approximately $13.4 million cumulatively, to non-affiliate investors. Revenue Breakdown and Summary of Installations / Surgeries CategoryQ4 2024Q4 2025VariancePercentageSystem sales$7,735,005$13,364,153$5,629,14872.8%Instrument sales282,332844,279561,947199.0%Warranty sales80,769316,771236,002292.2%Lease income18,0879,280(8,807)(48.7)%Total revenue$8,116,193$14,534,483$6,418,29079.1%     SSi Mantra installations22401881.8%Cumulative installed base165168103158.5%     SSi Mantra surgeries6101,8281,218199.7%Cumulative surgeries12,7597,8855,126185.8%           1 at period end Category20242025VariancePercentageSystem sales$19,457,767$38,353,048$18,895,28197.1%Instrument sales942,5483,183,7572,241,209237.8%Warranty sales177,518877,033699,515394.1%Lease income71,69570,909(786)(1.1)%Total revenue$20,649,528$42,484,747$21,835,219105.7%     SSi Mantra installations4710356119.1%SSi Mantra surgeries2,1395,0872,948137.8%      About SS Innovations SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi Mantra The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures. Forward Looking StatementsThis press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investor Contact:The Equity GroupKalle Ahl, CFAT: (303) 953-9878kahl@theequitygroup.com Devin Sullivan, Managing Director T: (212) 836-9608dsullivan@theequitygroup.com Media Contact:RooneyPartners LLCKate BarretteT: (212) 223-0561kbarrette@rooneypartners.com SS INNOVATIONS INTERNATIONAL, INC.CONSOLIDATED BALANCE SHEETS(Audited)  As of   December 31, 2025  December 31, 2024        ASSETS      Current Assets:      Cash and cash equivalents $3,206,406  $466,500 Restricted cash  5,937,650   5,838,508 Accounts receivable, net  12,398,542   4,466,047 Inventory, net  17,064,002   10,206,898 Prepaids and other current assets  10,194,059   6,438,338 Total Current Assets  48,800,659   27,416,291          Property, plant, and equipment, net  9,100,546   5,385,955 Right of use asset  2,754,020   2,623,880 Deferred tax assets, net  533,727   – Accounts receivable, net  8,566,654   3,299,032 Restricted cash  458,964   318,527 Prepaids and other non current assets  4,011,647   3,341,528 Total Assets $74,226,217  $42,385,213          LIABILITIES AND STOCKHOLDERS’ EQUITY        Current Liabilities        Bank overdraft facility $11,442,948  $7,994,906 Notes payable  –   7,450,000 Current portion of operating lease liabilities  579,169   409,518 Accounts payable  5,127,193   2,312,382 Deferred revenue  3,266,686   1,278,602 Accrued expenses & other current liabilities  5,825,702   1,884,814 Total Current Liabilities  26,241,698   21,330,222          Operating lease liabilities, less current portion  2,337,697   2,349,118 Deferred Revenue  7,139,807   5,173,953 Other non current liabilities  288,764   74,817 Total Liabilities $36,007,966  $28,928,110 Commitments and contingencies        Stockholders’ equity:                 Preferred stock, authorized 5,000,000 shares of Series A, Non-Convertible Preferred Stock, $0.0001 par value per share; 1,000 shares issued and outstanding as of December 31, 2025 and December 31, 2024  1   1 Common stock, 250,000,000 shares authorized, $0.0001 par value, 194,165,141 shares and 171,579,284 shares issued and outstanding as of December 31, 2025 and December 31, 2024 respectively  19,416   17,157 Accumulated other comprehensive income (loss)  (2,022,660)  (749,625)Additional paid in capital  95,111,511   56,952,200 Capital reserve  899,917   899,917 Accumulated deficit  (55,789,934)  (43,662,547)Total stockholders’ equity  38,218,251   13,457,103 Total liabilities and stockholders’ equity $74,226,217  $42,385,213  SS INNOVATIONS INTERNATIONAL, INC.CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Audited)  For the three months endedDecember 31,2025  For the threemonths endedDecember 31,2024      REVENUES     System sales  13,364,153   7,735,005 Instruments sale  844,279   282,332 Warranty sale  316,771   80,769 Lease income  9,280   18,087 Total revenue $14,534,483  $8,116,193 Cost of revenue  (8,157,430)  (4,147,202)        GROSS PROFIT  6,377,053   3,968,991         OPERATING EXPENSES:       Research & development expense  1,390,826   761,937 Stock compensation expense  2,023,433   2,338,887 Depreciation and amortization expense  309,491   145,926 Selling, general and administrative expense  3,388,300   2,560,927 TOTAL OPERATING EXPENSES  7,112,050   5,807,677         Loss from operations  (734,997)  (1,838,686)        OTHER INCOME (EXPENSE):       Interest Expense  (335,296)  (292,954)Interest and other income, net  364,566   208,249 TOTAL INCOME / (EXPENSE), NET  29,270   (84,705)        LOSS BEFORE INCOME TAXES  (705,727)  (1,923,391)Income tax expense  1,765,653   – NET LOSS $(2,471,380) $(1,923,391)        CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS               NET LOSS $(2,471,380) $(1,923,391)        OTHER COMPREHENSIVE INCOME (LOSS)       Foreign currency translation loss  (685,735)  (385,368)Retirement Benefit (net of tax)  (48,444)  (24,086)RECLASSIFICATION ADJUSTMENTS:       Retirement Benefit (net of tax)  1,433   – Income tax effects relating to retirement benefit  14,912   – TOTAL OTHER COMPREHENSIVE LOSS  (717,834)  (409,454)TOTAL COMPREHENSIVE LOSS $(3,189,214) $(2,332,845) SS INNOVATIONS INTERNATIONAL, INC.CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Audited)  For The Year Ended   December 31, 2025  December 31, 2024        REVENUES      System sales 38,353,048  19,457,767 Instruments sale  3,183,757   942,548 Warranty sale  877,033   177,518 Lease income  70,909   71,695 Total revenue $42,484,747  $20,649,528 Cost of revenue  (22,940,492)  (12,197,162)         GROSS PROFIT  19,544,255   8,452,366          OPERATING EXPENSES:        Research & development expense  3,685,840   2,491,771 Stock compensation expense  8,128,103   14,342,784 Depreciation and amortization expense  1,075,907   436,005 Selling, general and administrative expense  14,848,439   10,157,768 TOTAL OPERATING EXPENSES  27,738,289   27,428,328          Loss from operations  (8,194,034)  (18,975,962)         OTHER INCOME (EXPENSE):        Interest Expense  (1,108,637)  (973,235)Interest and other income, net  1,141,724   798,000 TOTAL INCOME / (EXPENSE), NET  33,087   (175,235)         LOSS BEFORE INCOME TAXES  (8,160,947)  (19,151,197)Income tax expense  3,966,440   – NET LOSS $(12,127,387) $(19,151,197)         Net loss per share – basic and diluted $(0.06) $(0.11)Weighted average – basic shares  190,009,159   170,847,444 Weighted average – diluted shares  198,699,461   181,203,673          CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS                 NET LOSS $(12,127,387) $(19,151,197)         OTHER COMPREHENSIVE INCOME (LOSS):        Foreign currency translation loss  (1,225,696)  (539,900)Retirement Benefit  (68,809)  (14,226)RECLASSIFICATION ADJUSTMENTS:        Retirement Benefit  1,433   – Income tax effects relating to retirement benefit  20,037   – TOTAL OTHER COMPREHENSIVE LOSS  (1,273,035)  (554,126)TOTAL COMPREHENSIVE LOSS $(13,400,422) $(19,705,323) SS INNOVATIONS INTERNATIONAL, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(Audited)  For the Year Ended   December 31, 2025  December 31, 2024 Cash flows from operating activities:             Net loss $(12,127,387) $(19,151,197)Adjustments to reconcile net loss to net cash used in operating activities:        Depreciation and amortization  1,075,907   436,005 Operating lease expense  827,521   753,449 Interest Expense  271,633   317,234 Interest and other income, net  (625,883)  (418,426)Property, plant and equipment written off  –   48,456 Provision for credit loss reserve, net  324,345   955,762 Deferred income tax benefit  (512,865)  – Stock compensation expense  8,128,103   14,342,784 Provision for slow moving inventory  (110,332)  –          Changes in operating assets and liabilities:        Accounts receivable, net  (13,037,284)  (4,890,032)Inventory, net  (8,070,786)  (7,691,518)Deferred revenue  3,953,938   5,357,075 Prepaids and other assets  (5,101,794)  (1,411,621)Accounts payable  2,877,810   1,410,830 Income taxes payable, net  4,214,339   – Accrued expenses & other liabilities  161,914   1,144,037 Operating lease payment  (792,166)  (705,868)Net cash used in operating activities  (18,542,987)  (9,503,030)         Cash flows from investing activities:        Purchase of property, plant and equipment  (3,659,058)  (661,479)Net cash used in investing activities  (3,659,058)  (661,479)         Cash flows from financing activities:        Proceeds from bank overdraft facility (net)  3,448,042   1,975,980 Proceeds from issuance of promissory notes to principal shareholder  –   3,000,000 Proceeds from issuance of convertible notes to principal shareholder  28,000,000   3,000,000 Proceeds from issuance of convertible notes to other investors  –   1,450,000 Repayment of convertible notes to principal shareholder, including interest  (4,212,637)  – Repayment of convertible notes to other investors, including interest  (1,068,849)  – Net cash provided by financing activities  26,166,556   9,425,980          Net change in cash  3,964,511   (738,529)Effect of exchange rate on cash  (985,026)  274,219 Cash and cash equivalents at the beginning of the year  6,623,535   7,087,845 Cash and cash equivalents at end of the year $9,603,020  $6,623,535 

Financing led by Certain of the Company’s Directors and Executive OfficersFORT LAUDERDALE, Fla., March 09, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that on March 6, 2026, the Company completed a private placement of its common stock (the “Private Placement”) which generated approximately $18.6 million in gross proceeds, before deducting offering expenses. In the offering, the Company offered and sold a total of 5,774,839 shares of common stock consisting of: an aggregate of 1,300,006 shares of common stock at an average price of $4.00 per share, or a total of approximately $5.2 million, to Dr. Sudhir Srivastava, our Chairman and Chief Executive Officer ($2.0 million), Dr. Frederic H. Moll, our Vice-Chairman ($2.0 million), and Tim Adams, a director ($1.197 million); andan aggregate of 4,474,833 shares of common stock at $3.00 per share, or a total of approximately $13.4 million, to existing and new investors, led by Manipal Global Health Services, an existing shareholder.   SS Innovations intends to use the net proceeds from this financing for working capital and other general corporate purposes, including advancing the Company’s global expansion efforts. In connection with a $2.5 million investment by one of the non-affiliate investors in the Private Placement, SS Innovations will pay a FINRA member firm a cash commission of $175,000 (7% of the investment) and issue to such firm five-year warrants to purchase 41,667 shares of our common stock at an exercise price of $3.45 per share. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “The net proceeds from this financing will advance our growth initiatives in India and other existing global markets, while supporting our preparation for entry into the United States and European Union markets. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for our SSi Mantra surgical robotic system by mid-2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can also obtain in 2026.” Dr. Srivastava continued, “Insider participation in this financing reflects our strong confidence in SS Innovations’ future and our commitment to democratizing access to world-class surgical robotic care. We appreciate the continuing support of Manipal Global Health Services, a large existing shareholder, and welcome a respected group of new shareholders in the Company.” The securities being sold in the Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws and accordingly may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About SS Innovations SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi Mantra The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures. Forward Looking StatementsThis press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we do not assume any obligation to update any forward-looking statement. Investor Contact:The Equity Group        Kalle Ahl, CFA                T: (303) 953-9878        kahl@theequitygroup.com Devin Sullivan, Managing Director T: (212) 836-9608dsullivan@theequitygroup.com Media Contact:RooneyPartners LLCKate BarretteT: (212) 223-0561kbarrette@rooneypartners.com